{"id":38305,"date":"2022-06-06T02:08:39","date_gmt":"2022-06-06T02:08:39","guid":{"rendered":"https:\/\/harchi90.com\/enhertu-dramatically-extends-survival-in-breast-cancer-patients\/"},"modified":"2022-06-06T02:08:39","modified_gmt":"2022-06-06T02:08:39","slug":"enhertu-dramatically-extends-survival-in-breast-cancer-patients","status":"publish","type":"post","link":"https:\/\/harchi90.com\/enhertu-dramatically-extends-survival-in-breast-cancer-patients\/","title":{"rendered":"Enhertu dramatically extends survival in breast cancer patients"},"content":{"rendered":"<div id=\"\">\n<p><span class=\"big-cap-wrap\"><span class=\"big-cap\">C.<\/span><\/span>HICAGO &#8211; The cancer drug Enhertu cut the rate of death in a group of women with advanced breast cancer by a third in a new clinical trial, a result that oncologists said could shift the way they think about treating the disease.<\/p>\n<p>The makers of the medicine, Daiichi Sankyo and AstraZeneca, said that, if regulators clear the way, the number of patients eligible to receive the drug could be tripled, meaning that thousands of women in the US alone could be offered a new life-extending option.<\/p>\n<div class=\"restricted-content-breaker\">\n<div class=\"restricted-content-wrapper\">\n<div class=\"restricted-content-message\">\n<p class=\"restricted-content-text\">\n<p>\t\t\t\t\t\tUnlock this article by subscribing to STAT + and enjoy your first 30 days free!\t\t\t\t\t<\/p>\n<p>\t\t\t\t\tGET STARTED\n\t\t\t\t<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<p><script>\n\t\t\t\twindow.statGlobal = window.statGlobal || { };\n\t\t\t\twindow.statGlobal.analytics = window.statGlobal.analytics || { };<\/p>\n<p>\t\t\t\twindow.statGlobal.analytics.fbq = function( eventName, parameters ) {\n\t\t\t\t\tjQuery.ajax( {\n\t\t\t\t\t\turl: '\/wp-json\/stat-analytics\/v1\/facebook-pixel',\n\t\t\t\t\t\ttype: 'POST',\n\t\t\t\t\t\tdata: {\n\t\t\t\t\t\t\tevent_name: !eventName ? null : eventName,\n\t\t\t\t\t\t\tparameters: !parameters ? {} : parameters,\n\t\t\t\t\t\t\tsource_url: window.location.href\n\t\t\t\t\t\t},\n\t\t\t\t\t\tsuccess: function( data, textStatus, jqXHR ) {\n\t\t\t\t\t\t\t\/\/console.log( data );\n\t\t\t\t\t\t},\n\t\t\t\t\t\terror: function ( jqXHR, textStatus, errorThrown ) {\n\t\t\t\t\t\t\t\/\/console.log( jqXHR );\n\t\t\t\t\t\t}\n\t\t\t\t\t} );\n\t\t\t\t};<\/p>\n<p>\t\t\t\tjQuery( window ).on( 'load', function() {\n\t\t\t\t\tif ( !window.bgmpGdpr || window.bgmpGdpr.isOptedOut() ) {\n\t\t\t\t\t\treturn;\n\t\t\t\t\t}<\/p>\n<p>\t\t\t\t\t!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod?\n\t\t\t\t\tn.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;\n\t\t\t\t\tn.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;\n\t\t\t\t\tt.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,\n\t\t\t\t\tdocument,'script','https:\/\/connect.facebook.net\/en_US\/fbevents.js');<\/p>\n<p>\t\t\t\t\tfbq( 'init', '436331036555416' );\n\t\t\t\t\tfbq( 'track', 'PageView' );<\/p>\n<p>\t\t\t\t\tif ( 'object' === typeof mc4wp && mc4wp.forms ) {\n\t\t\t\t\t\tmc4wp.forms.on( 'subscribed', function() {\n\t\t\t\t\t\t\t\/\/ Successful MC4WP newsletter signup AJAX form submission.\n\t\t\t\t\t\t\twindow.statGlobal.analytics.fbq( 'Lead' );\n\t\t\t\t\t\t} );\n\t\t\t\t\t}\n\t\t\t\t\t\t\t\twindow.statGlobal.analytics.fbq( 'ViewContent' );\n\t\t\t\t\t\t\t\t} );\n\t\t\t<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>C.HICAGO &#8211; The cancer drug Enhertu cut the rate of death in a group of women with advanced breast cancer by a third in a new clinical trial, a result that oncologists said could shift the way they think about treating the disease. The makers of the medicine, Daiichi Sankyo and AstraZeneca, said that, if &hellip;<\/p>\n<p class=\"read-more\"> <a class=\"\" href=\"https:\/\/harchi90.com\/enhertu-dramatically-extends-survival-in-breast-cancer-patients\/\"> <span class=\"screen-reader-text\">Enhertu dramatically extends survival in breast cancer patients<\/span> Read More &raquo;<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","spay_email":"","jetpack_publicize_message":"","jetpack_is_tweetstorm":false,"jetpack_publicize_feature_enabled":true},"categories":[8],"tags":[],"jetpack_featured_media_url":"","jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"fifu_image_url":"https:\/\/www.statnews.com\/wp-content\/uploads\/2022\/06\/AP6211315698666588-1024x576.jpg","_links":{"self":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/posts\/38305"}],"collection":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/comments?post=38305"}],"version-history":[{"count":0,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/posts\/38305\/revisions"}],"wp:attachment":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/media?parent=38305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/categories?post=38305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/tags?post=38305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}